Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
INDIANAPOLIS (AFX) - Eli Lilly and Company said the US Food and Drug Administration has approved its drug Gemzar for use in the treatment of women living with recurrent ovarian cancer.
The company said this is the fourth approval its second best-selling drug has been granted by the FDA which specifies that the anti-cancer agent can be used in combination with carboplatin, a widely-used agent, for women with advanced ovarian cancer that has relapsed at least six months after initial therapy. newsdesk@afxnews.com ks COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Copyright 2006 AFX News Limited. All Rights Reserved.
